PATENT CLAIM ANALYSIS

Application Number: 15779873
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "171000"]

Abstract:
Selective cancer treatment regimes based on assaying for the presence or absence of a mutation in PI3K in a blood or serum sample obtained from a patient having cancer. The cancer is treated with 5-(2,6-di-mor-pholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine or its hydrochloride salt, or (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) on the basis that the patient is determined to have in their ctDNA a PIK3CA mutation.

Claim (Index 26):
The method according to  claim 9 , wherein the cancer is breast cancer.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 93.0
- Lexical Diversity: 1.37705
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15646494', '13799076', '14387653', '14240499', '14429367']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8311473312255133
- 35 USC 102 Novelty (BERT): 0.5502514830981913
- Combined Prediction Score: 0.803057746412781
- Mean Citation Score: 412.218016
- Max Citation Score: 496.98544
- Similarity Product: 253.0833109926509

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test